Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperaesthesia23.03.03.080; 17.02.06.0040.000066%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.000286%
Hypercalciuria20.02.01.007; 14.04.01.006; 05.04.01.0030.000088%Not Available
Hypercapnia22.02.02.002; 14.01.04.0010.000044%Not Available
Hypercholesterolaemia14.08.01.0010.003236%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000440%
Hyperkalaemia14.05.03.0010.000286%
Hyperkeratosis23.01.01.0010.000220%
Hypernatraemia14.05.04.0010.000044%
Hyperparathyroidism05.04.01.001; 14.04.01.0200.000462%
Hyperparathyroidism primary14.04.01.021; 05.04.01.0050.000132%Not Available
Hyperparathyroidism secondary14.04.01.022; 20.01.01.006; 05.04.01.0040.000066%Not Available
Hypersensitivity10.01.03.0030.000938%
Hypersomnia17.15.01.001; 19.02.05.0010.000066%
Hypertension24.08.02.0010.008836%
Hypertensive heart disease02.11.02.001; 24.08.05.0020.000154%Not Available
Hyperthyroidism05.02.02.001; 14.11.01.0110.000330%
Hypertonic bladder20.03.03.003; 17.10.01.0030.000440%Not Available
Hypertriglyceridaemia14.08.02.0010.000088%
Hypertrophy08.03.04.0050.000088%Not Available
Hyperuricaemia14.09.01.0030.000066%
Hypervolaemia02.05.04.019; 14.05.06.0030.000110%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.000845%Not Available
Hypoalbuminaemia14.10.01.002; 09.01.02.0030.000110%
Hypocalcaemia14.04.01.0040.000339%
Hypogammaglobulinaemia10.03.02.0070.000044%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000440%
Hypokalaemia14.05.03.0020.001321%
Hypokinesia17.01.02.0090.000141%Not Available
Hypomagnesaemia14.04.02.0010.000242%
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 39 Pages